Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Coronavirus
Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
HIV Test
September 29, 2020
  Today, more than 50% of all people living with HIV in the United States are over the age of 50. Ten years from now that percentage is estimated to go up to 70% and more than four in five people…
Patient & Health Advocacy Summit Digital
September 23, 2020
This year has feels like an unfair pile on. One crisis follows another while the first never gets resolved. From the pandemic to global recession to civil unrest to raging fires to hurricanes, the relentless onslaught…
fight-covid-19-bio.png
September 16, 2020
In case you missed it, the Trump administration is moving forward with a plan to import into the United States dangerous government price setting for innovative cures and treatments. In a nutshell, the move will harm…
Press Releases
September 24, 2020
Event Highlighted Leadership in Vaccine Development and Regional Growth in Biotechnology Innovation Gaithersburg, MD (September 24, 2020) – Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology Innovation Organization (BIO), joined Novavax…
June 16, 2020
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee members for the 2020-2021 term. Additionally, eight new board directors and four new section governing board chairs and vice chairs were elected. BIO’s Board elections took place…
May 13, 2020
Following the announcement that Dr. Moncef Slaoui will lead the Trump Administration's "Operation Warp Speed" initiative, BIO’s President and CEO, Jim Greenwood, issued the following statement:  “Dr. Moncef Slaoui is an excellent choice to lead the President’s Operation Warp Speed…
Letters, Comments & Testimony
September 28, 2020
September 22, 2020 Re: Docket No. FDA-2019-N-5553: Annual Summary Reporting Requirements Under the Right to Try Act, Proposed Rule Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments…
September 28, 2020
September 27, 2020 Re: Docket No. FDA-2014-D-1551:  FDA Draft Guidance, Pregnancy, Lactation, and Reproductive Potential:  Labeling for Human Prescription Drug and Biological Products – Content and Format. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food…
July 31, 2020
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the Request for…
Patient-Take-Action
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.